Muhammad Jamil, MD
Hematology & Oncology · Huntington, WVNPI 1245545508
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $343 of the $438 with a category attached, or 78.3%. 12 manufacturers reported payments, led by AbbVie at 27.2% of the total. That places this record below the midpoint for hematology & oncology clinicians in WV, where the typical reported total is $1,186.
Across 23 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$119
- E.r. Squibb & Sons, L.L.C.$58
- Merck$52
- Pfizer$47
- Daiichi Sankyo Inc.$27
- AstraZeneca$24
- plus $110 from 6 others
What the payments were for
- Food & beverage$34378%
- Education$9522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $119 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Merck | 3 | $52 |
| Pfizer | 3 | $47 |
| Daiichi Sankyo Inc. | 1 | $27 |
| AstraZeneca | 1 | $24 |
| Galvanize Therapeutics, Inc | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Seagen Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $11 |
How this compares
$438 in reported general payments places this provider in the 35th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 96 | $1,261,838 |
| IbrancePalbociclib | 50 | $807,220 |
| PomalystPomalidomide | 30 | $718,126 |
| VenclextaVenetoclax | 48 | $639,091 |
| InlytaAxitinib | 26 | $456,662 |
| IdhifaEnasidenib Mesylate | 12 | $416,089 |
| PromactaEltrombopag Olamine | 37 | $413,900 |
| CabometyxCabozantinib S-Malate | 16 | $380,528 |
| Abiraterone Acetate | 121 | $365,369 |
| SprycelDasatinib | 31 | $303,004 |
| NinlaroIxazomib Citrate | 25 | $297,707 |
| RevlimidLenalidomide | 17 | $268,452 |
| LynparzaOlaparib | 16 | $250,473 |
| TagrissoOsimertinib Mesylate | 13 | $206,636 |
| ImbruvicaIbrutinib | 13 | $148,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Eliquis | $47 | $1,361,810209 claims |
| Astellas Pharma US IncXtandi | $11 | $1,261,83896 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $58 | $1,021,13061 claims |
| AbbVieVenclexta | $119 | $639,09148 claims |
| AstraZenecaLynparza, Tagrisso | $24 | $457,10929 claims |
| Lilly USA, LLCOlanzapine | $22 | $25215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Huntington
- Damian SilberminsHuntington$277K
- Arvinder BirHuntington$74K
- Matias ValsecchiHuntington$17K
- Mina ShenoudaHuntington$3K
- Chathula KumarasingheHuntington$3K
- Toni PaciolesHuntington$747
- Maria TironaHuntington$252
- Oscar BallesterHuntington$119
- Abraham KanateMorgantown$169K
- Salman OsmanBridgeport$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.